BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

7506

532300

WOCKPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

WOCKHARDT LIMITED performance

Today’s low

Today’s high

₹ 1282.20 ₹ 1354.00
₹ 1296.70

52 week low

52 week high

₹ 490.15 ₹ 1679.90
₹ 1296.70

Open Price

₹ 1321.40

Prev. Close

₹ 1363.70

Volume (Shares)

400049.00

Total traded value

₹ 5187.43

Upper Circuit

₹ 1500.00

Lower Circuit

₹ 1227.40

info

WOCKHARDT LIMITED Share Price Update

As of the latest trading session, WOCKHARDT LIMITED share price is currently at ₹ 1296.7, which is down by ₹ -67.00 from its previous closing. Today, the stock has fluctuated between ₹ 1282.20 and ₹ 1354.00. Over the past year, WOCKHARDT LIMITED has achieved a return of 137.04 %. In the last month alone, the return has been -5.81 %. Read More...

WOCKHARDT LIMITED fundamentals


  • Market cap (Cr)

    18,680.28

  • P/E Ratio (TTM)

    -118.42

  • Beta

    1.56

  • Book Value / share

    170.15

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -22.00

info icon alternate text
  • Market cap (Cr)

    18,680.28

  • P/E Ratio (TTM)

    -118.42

  • Beta

    1.48

  • Book Value / share

    170.15

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -22.00

info icon alternate text

WOCKHARDT LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 325.00
Operating Expense 353.00
Net Profit -22.00
Net Profit Margin (%) -6.76
Earnings Per Share (EPS) -1.40
EBITDA 68.00
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 370.00
Operating Expense 417.00
Net Profit -36.00
Net Profit Margin (%) -9.72
Earnings Per Share (EPS) -2.34
EBITDA 60.00
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 352.00
Operating Expense 373.00
Net Profit 6.00
Net Profit Margin (%) 1.70
Earnings Per Share (EPS) 0.39
EBITDA 107.00
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 355.00
Operating Expense 505.00
Net Profit -126.00
Net Profit Margin (%) -35.49
Earnings Per Share (EPS) -8.71
EBITDA -22.00
Effective Tax Rate (%) 0.00
Particulars DEC 2023 (Values in Cr)
Revenue 288.00
Operating Expense 367.00
Net Profit -74.00
Net Profit Margin (%) -25.69
Earnings Per Share (EPS) -5.14
EBITDA 30.00
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 1154.00
Operating Expense 1603.00
Net Profit -422.00
Net Profit Margin (%) -36.56
Earnings Per Share (EPS) -29.27
EBITDA -9.00
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 1072.00
Operating Expense 1417.00
Net Profit -466.00
Net Profit Margin (%) -43.47
Earnings Per Share (EPS) -32.40
EBITDA -98.00
Effective Tax Rate (%) 9.16
Particulars MAR 2022 (Values in Cr)
Revenue 1372.00
Operating Expense 1594.00
Net Profit -140.00
Net Profit Margin (%) -10.20
Earnings Per Share (EPS) -11.62
EBITDA 260.00
Effective Tax Rate (%) 23.91
Particulars MAR 2021 (Values in Cr)
Revenue 987.00
Operating Expense 1509.00
Net Profit 593.00
Net Profit Margin (%) 60.08
Earnings Per Share (EPS) 53.57
EBITDA -239.00
Effective Tax Rate (%) 37.07
Particulars MAR 2020 (Values in Cr)
Revenue 890.06
Operating Expense 1416.76
Net Profit -231.12
Net Profit Margin (%) -25.96
Earnings Per Share (EPS) -20.88
EBITDA -90.12
Effective Tax Rate (%) 32.66
Particulars MAR 2024 (Values in Cr)
Book Value / Share 218.12
ROE % -12.34
ROCE % -0.86
Total Debt to Total Equity 0.68
EBITDA Margin 6.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 232.92
ROE % -9.21
ROCE % -0.45
Total Debt to Total Equity 0.61
EBITDA Margin 8.45
Particulars MAR 2022 (Values in Cr)
Book Value / Share 267.29
ROE % -3.06
ROCE % 1.15
Total Debt to Total Equity 0.67
EBITDA Margin 9.85
Particulars MAR 2021 (Values in Cr)
Book Value / Share 306.91
ROE % 27.45
ROCE % 13.00
Total Debt to Total Equity 1.03
EBITDA Margin 38.92
Particulars MAR 2020 (Values in Cr)
Book Value / Share 241.26
ROE % -1.62
ROCE % 0.46
Total Debt to Total Equity 1.20
EBITDA Margin 8.87
Particulars MAR 2024 (Values in Cr)
Book Value / Share 116.62
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.17
EBITDA Margin -0.78
Particulars MAR 2023 (Values in Cr)
Book Value / Share 121.74
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.02
EBITDA Margin 12.78
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.61
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.07
EBITDA Margin 18.95
Particulars MAR 2021 (Values in Cr)
Book Value / Share 146.00
ROE % 56.52
ROCE % -7.40
Total Debt to Total Equity 1.71
EBITDA Margin -9.83
Particulars MAR 2020 (Values in Cr)
Book Value / Share 89.82
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.64
EBITDA Margin 0.50
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 124.00
Total Assets 7683.00
Total Liabilities 7683.00
Total Equity 3662.00
Share Outstanding 144060153
Price to Book Ratio 1.26
Return on Assets (%) -7.27
Return on Capital (%) -10.07
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 406.00
Total Assets 8243.00
Total Liabilities 8243.00
Total Equity 4202.00
Share Outstanding 144060153
Price to Book Ratio 1.72
Return on Assets (%) -2.96
Return on Capital (%) -4.02
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 292.00
Total Assets 7774.00
Total Liabilities 7774.00
Total Equity 3759.00
Share Outstanding 110781153
Price to Book Ratio 2.84
Return on Assets (%) 8.82
Return on Capital (%) 11.26
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 268.46
Total Assets 8178.91
Total Liabilities 8178.91
Total Equity 3057.46
Share Outstanding 110735003
Price to Book Ratio 1.92
Return on Assets (%) -0.84
Return on Capital (%) -1.33
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 448.65
Total Assets 7844.31
Total Liabilities 7844.31
Total Equity 3004.63
Share Outstanding 110686203
Price to Book Ratio 4.00
Return on Assets (%) -2.47
Return on Capital (%) -3.56
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 486.00
Total Assets 4868.00
Total Liabilities 4868.00
Total Equity 1796.00
Share Outstanding 153400936
Price to Book Ratio 5.00
Return on Assets (%) -8.66
Return on Capital (%) -11.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 37.00
Total Assets 4732.00
Total Liabilities 4732.00
Total Equity 1753.00
Share Outstanding 144060153
Price to Book Ratio 1.26
Return on Assets (%) -9.84
Return on Capital (%) -13.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 207.00
Total Assets 5798.00
Total Liabilities 5798.00
Total Equity 2212.00
Share Outstanding 144060153
Price to Book Ratio 1.72
Return on Assets (%) -2.41
Return on Capital (%) -3.68
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 138.00
Total Assets 4895.00
Total Liabilities 4895.00
Total Equity 1606.00
Share Outstanding 110781153
Price to Book Ratio 2.84
Return on Assets (%) 12.11
Return on Capital (%) 18.42
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 157.48
Total Assets 4759.51
Total Liabilities 4759.51
Total Equity 994.62
Share Outstanding 110735003
Price to Book Ratio 1.92
Return on Assets (%) -4.85
Return on Capital (%) -9.65
Particulars MAR 2024 (Values in Cr)
Net Income -420.00
Cash from Operations 249.00
Cash from Investing -137.00
Cash from Financing 334.00
Net change in Cash 416.00
Free Cash Flow 308.00
Particulars MAR 2023 (Values in Cr)
Net Income -624.00
Cash from Operations 164.00
Cash from Investing -125.00
Cash from Financing -315.00
Net change in Cash -287.00
Free Cash Flow 206.00
Particulars MAR 2022 (Values in Cr)
Net Income -411.00
Cash from Operations 510.00
Cash from Investing -201.00
Cash from Financing -71.00
Net change in Cash 141.00
Free Cash Flow 628.00
Particulars MAR 2021 (Values in Cr)
Net Income 916.00
Cash from Operations -170.00
Cash from Investing 1470.00
Cash from Financing -1171.00
Net change in Cash 12.00
Free Cash Flow -89.00
Particulars MAR 2020 (Values in Cr)
Net Income -196.68
Cash from Operations 666.12
Cash from Investing -155.53
Cash from Financing -679.58
Net change in Cash -186.15
Free Cash Flow 696.77
Particulars MAR 2024 (Values in Cr)
Net Income -422.00
Cash from Operations 188.00
Cash from Investing -75.00
Cash from Financing 346.00
Net change in Cash 459.00
Free Cash Flow 190.00
Particulars MAR 2023 (Values in Cr)
Net Income -513.00
Cash from Operations 76.00
Cash from Investing -3.00
Cash from Financing -236.00
Net change in Cash -168.00
Free Cash Flow 76.00
Particulars MAR 2022 (Values in Cr)
Net Income -184.00
Cash from Operations -14.00
Cash from Investing -244.00
Cash from Financing 430.00
Net change in Cash 93.00
Free Cash Flow 38.00
Particulars MAR 2021 (Values in Cr)
Net Income 861.00
Cash from Operations -452.00
Cash from Investing 1014.00
Cash from Financing -480.00
Net change in Cash -29.00
Free Cash Flow -435.00
Particulars MAR 2020 (Values in Cr)
Net Income -338.32
Cash from Operations 222.01
Cash from Investing -16.15
Cash from Financing -273.97
Net change in Cash -68.61
Free Cash Flow 240.32
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

WOCKHARDT LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1296.70 -4.91 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 1360.50
  • 26 Days 1373.70
  • 10 Days 1373.40
  • 50 Days 1371.40
  • 12 Days 1374.50
  • 100 Days 1336.00
  • 20 Days 1374.40
  • 200 Days 1192.90
1380.23 PIVOT

First Support

1333.47

First Resistance

1410.47

Second Support

1303.23

Second Resistance

1457.23

Third Support

1256.47

Third Resistance

1487.47

RSI

42.78

ADX

25.42

MACD

0.82

Williams % R

-62.05

Commodity Channel Index (CCI)

-68.83

Date

2025-04-30

Week

247384.00

Same Day

198466.00

Month

275706.00

1 Year

1.56

3 Year

1.21

Over 1 Month

-5.81%

down

Over 1 Year

137.04%

down

Over 3 Months

2.88%

down

Over 3 Years

70.41%

down

Over 6 Months

24.01%

down

Over 5 Years

41.27%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

WOCKHARDT LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
33.51%
Promoter Holdings
49.08%
FII
6.81%
DII
10.58%
Promoter Shares(Pledge Percentage)
18.24%
Name Shares Category
Themisto Trustee Company Private Limited 6.5244744E7 (40.15%) Shareholding of Promoter and Promoter Group
Pasithee Trustee Company Private Limited 4420000.0 (2.72%) Shareholding of Promoter and Promoter Group
Ananke Trustee Company Private Limited 3810693.0 (2.35%) Shareholding of Promoter and Promoter Group
Callirhoe Trustee Company Private Limited 3112079.0 (1.92%) Shareholding of Promoter and Promoter Group
Rekha Jhunjhunwala 2837005.0 (1.75%) Public Shareholding
Tata Mutual Fund - Tata Small Cap Fund 2659133.0 (1.64%) Public Shareholding
3p India Equity Fund 1 2632333.0 (1.62%) Public Shareholding
Hdfc Large And Mid Cap Fund 1931625.0 (1.19%) Public Shareholding
Hsbc Small Cap Fund 1645008.0 (1.01%) Public Shareholding
Callirhoe Trustee Company Private Limited 936751.0 (0.58%) Shareholding of Promoter and Promoter Group
Pasithee Trustee Company Private Limited 650000.0 (0.4%) Shareholding of Promoter and Promoter Group
Habil F Khorakiwala 595486.0 (0.37%) Shareholding of Promoter and Promoter Group
Murtaza Habil Khorakiwala 294060.0 (0.18%) Shareholding of Promoter and Promoter Group
Huzaifa Habil Khorakiwala 280800.0 (0.17%) Shareholding of Promoter and Promoter Group
Ananke Trustee Company Private Limited 274530.0 (0.17%) Shareholding of Promoter and Promoter Group
Themisto Trustee Company Private Limited 130000.0 (0.08%) Shareholding of Promoter and Promoter Group
Khorakiwala Holdings And Investments Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Palanpur Holdings And Investments Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dartmour Holdings Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Zahabiya Khorakiwala 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Muayyad H Khorakiwala 1800.0 (0.0%) Shareholding of Promoter and Promoter Group
Miqdad H Khorakiwala 2340.0 (0.0%) Shareholding of Promoter and Promoter Group
Nafisa Habil Khorakiwala 5565.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

WOCKHARDT LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Nov 2016 10.0 Interim 19 Nov 2016 Equity shares
13 Nov 2014 20.0 Interim 15 Nov 2014 Equity shares
17 Feb 2014 5.0 Interim 2 19 Feb 2014 Equity shares
07 Nov 2013 5.0 Interim 08 Nov 2013 Equity shares
22 Aug 2013 5.0 Final 24 Aug 2013 Equity shares
17 Apr 2008 2.5 Final 22 Apr 2008 Equity shares
26 Oct 2007 8.75 Interim 29 Oct 2007 Equity shares
22 Mar 2007 5.0 Interim 23 Mar 2007 Equity shares
21 Jun 2006 0.0 Final 23 Jun 2006 Equity shares
Ex-Date Ex-Bonus Ratio
07 May 2004 28 Apr 2004 1:2
Ex-Date Old FV NEW FV Record Date
28 Apr 2004 10.0 5.0 07 May 2004
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Nov 2016 10.0 Interim 19 Nov 2016 Equity shares
13 Nov 2014 20.0 Interim 15 Nov 2014 Equity shares
17 Feb 2014 5.0 Interim 2 19 Feb 2014 Equity shares
07 Nov 2013 5.0 Interim 08 Nov 2013 Equity shares
22 Aug 2013 5.0 Final 24 Aug 2013 Equity shares
17 Apr 2008 2.5 Final 22 Apr 2008 Equity shares
26 Oct 2007 8.75 Interim 29 Oct 2007 Equity shares
22 Mar 2007 5.0 Interim 23 Mar 2007 Equity shares
21 Jun 2006 0.0 Final 23 Jun 2006 Equity shares
Ex-Date Ex-Bonus Ratio
07 May 2004 28 Apr 2004 1:2
Ex-Date Old FV NEW FV Record Date
28 Apr 2004 10.0 5.0 07 May 2004

Wockhardt Share Result Highlights 

Wockhardt's performance shows a 7.44% YoY sales growth in Q2 of this financial year, with revenue rising to ₹809 crore from ₹753 crore a year ago. It is also 70 crore higher than the first quarter of this year. However, the company reported a net loss of ₹16 crore, though this represents a significant 78% improvement in YoY profit, when compared to the same quarter last year. The operating profit reached ₹110 crore with a stable OPM of 14%, reflecting operational efficiency despite challenges.

Wockhardt Share Annual Reports

For FY24, Wockhardt’s revenue reached ₹2,798 crore, marking a 5.55% growth from ₹2,651 crore in FY23. However, net losses persisted, narrowing slightly to ₹472 crore compared to ₹621 crore the prior year. The company’s EPS stood at -₹30.18, reflecting ongoing challenges in profitability. Over the past three years, Wockhardt has shown a slight recovery in sales growth (1%), but negative returns on equity (-8% on average) highlight the need for operational improvements. These figures indicate Wockhardt’s slow but gradual turnaround amid a challenging pharmaceutical landscape. Interestingly, Wockhardt’s share price in the last 1 year period surged to 292%.

Wockhardt Share Dividend

Wockhardt did not declare any dividends for FY24, as it prioritised stabilising operations amid ongoing losses. The company’s dividend yield remains at 0%, reflecting its focus on reinvesting to address its financial challenges. Despite a 78% YoY improvement in Q2 profits, net losses and negative equity returns (-12% last year) underscore the difficulty of achieving dividend payouts. A noteworthy factor, here, is Wockhardt’s compounded profit growth of 16% over three years. 

Additional FAQs

1. Who is the CEO of Wockhardt Ltd?

Dr. Habil Khorakiwala is the Founder and Chairman of Wockhardt Ltd, while Dr. Murtaza Khorakiwala is the company’s Managing Director.

 

2. When was Wockhardt Ltd established?

Wockhardt Ltd was established in 1967 and has grown into a global pharmaceutical and biotechnology company with a strong focus on innovation.

 

3. What factors influence the Wockhardt Share Price?

Wockhardt’s share price is influenced by factors such as product pipeline development, regulatory approvals, operational performance, and demand for its pharmaceutical offerings globally.

 

4. Is Wockhardt Ltd debt free?

No, Wockhardt Ltd is not debt free, as the company utilises financing to support its research, development, and expansion activities.

 

5. What is the CAGR of Wockhardt Share?

The CAGR of Wockhardt’s share is 5% over 10 years, 41% over 5 years, and 50% over 3 years.

 

6. How has the Wockhardt Share Price performed over the past year?

Over the past year, Wockhardt’s share price has seen a meteoric rise of 292%, driven by positive developments in its product offerings and improved financial performance.

 

WOCKHARDT LIMITED Share Price

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out.

The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'. Wockhardt's entire anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.

In 2000, the company launched the cardiac drug enalapril maleate in the US through their marketing joint venture with Sidmak Laboratories. Also, they set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad.

In the year 2001, the company terminated their three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic Pharma companies in the US. Also, they entered into a strategic alliance with a Japanese firm Eisai Company Ltd to manufacture and market a neurology drug Methycobal.

In the year 2003, the company restructured their field organization to upgrade their competitiveness and productivity, launched new four speciality hospitals at their Mulund complex in Mumbai. Also, they acquired CP pharmaceuticals (Holdings) Ltd, along with their subsidiaries. The company launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. Also, they received USFDA approval for marketing bethanecol Chloride tablets in the US.

In the year 2004, the company acquired the German pharmaceutical company esparma GmbH for a consideration of Rs 49 crore. Also, they got USFDA nod for 6 manufacturing units.

In February 2005, the company launched India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients. The company forged alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad. Also, they received US FDA approval for marketing cefuroxime axetil in the US market. In the year 2006, the US FDA had approved the company's Waluj plant.

In the year 2007, the company signed in-licensing pact with Crawford Healthcare of UK. They acquired Negma Laboratories, which is the fourth largest independent, integrated pharmaceutical groups in France, for an all-cash deal worth $ 265 million. In October 2007, they acquired the Morton Grove Pharmaceuticals, a leading liquid generic and speciality dermatology company in the US. Also, they inked an in-licensing agreement with the Italy-based Gnosis, to market SAMe (S-adenosyl methionine).

In the year 2008, the company approved demerger of their Research & Development business into a separate entity. Also, they launched the Cetirizine tablets in the USA. The company received the ANDA from the US FDA for marketing the tablets containing 5mg and 10mg Cetirizine Hydrochloride.

In February 2008, they received approval from the US FDA for marketing the tablets containing 250 mg, 500 mg and 600 mg Azithromycin. In August 2008, the company received tentative approval from the US FDA to make and sell Sumatriptan Succinate injection, in the strength of 6-mg/0.5 ml.

During the period January 2009 to March 2010, the company received 22 ANDA approvals and launched eight new products, thereby expanding their product basket to 87. During the period, the company divested Animal Health Care Division to Vetoquinol, France. The business of Esparma GmbH was also divested to Mova GmbH.

During the year 2010-11, the company launched a total of 43 new products in India. In April 2011, as per the scheme of arrangement, the Nutrition Business of Vinton Healthcare Ltd, a wholly owned subsidiary of the company was demerged into the company. The appointed date for the Scheme is January 1, 2011.

In January 2012, the company received final approval from the United States Food & Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis.

In 2012, the company launches generic version of anti--ulcer drug Prevacid. The company also receives US FDA approval for generic version of Parkinsonism drug Requip XL. The company receives tentative US FDA approval for generic version of anti-psychotic drug Geodon. The company also receives US FDA approval for generic version of Parkinson's drug Comtan.

In 2013, the company Wockhardt receives the 'Best Enterprise' award from the Europe. The company launches launches generic version of anti-convulsant drug Lamictal XR.

In 2015, the company receives ANDA Approval for pain medication Oxycodone liquid. The company also receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA. US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt.

On 15 January 2016, Wockhardt Ltd informed the stock exchanges that inspection of its manufacturing unit at E-1/1, MIDC, Shendra, Aurangabad by US FDA has since been completed. US FDA has made 9 observations for which appropriate reply would be submitted to inspecting authority in due course. Shendra manufacturing unit is a new facility and presently there is no supply of products from the said Unit to USA markets.

On 1 July 2016, Wockhardt Ltd informed the stock exchanges that the Company has given Corporate Guarantee to secure Term loan of US$ 250 Million facility availed by Wockhardt Bio AG, a subsidiary of the Company.

On 8 August 2016, Wockhardt informed the stock exchanges that U.S. Food and Drug Administration (USFDA) has updated Import Alert 66-40 on its website on Wockhardt's API (Active Pharmaceutical Ingredients) unit located in Ankleshwar, Gujarat. The company has already initiated required steps to address the concerns raised by USFDA and putting all efforts to resolve the matter.

With reference to the earlier letter dated 8 August 2016 regarding Update on Import Alert 66-40 by US FDA on Wockhardt's API Unit at Ankleshwar, Gujarat, Wockhardt Ltd informed the stock exchanges on 3 October 2016 that U.S. Food and Drug Administration (USFDA') on 30 September 2016 has posted on its website an update on the above referred matter and excluded the product 'Ceftriazone Sodium' from Import Alert. This will enable the Company to manufacture and sell Ceftriazone API and formulation to US market.

The Board of Directors of Wockhardt at their Meeting held on 10 November 2016 approved the acquisition of 100% stake in Wockhardt France (Holdings) S.A.S. (WFH') (an existing step down subsidiary of the Company) from Wockhardt Bio AG (WBG'), a subsidiary of the Company. By virtue of the said acquisition, WFH shall become a direct wholly owned subsidiary of the Company from erstwhile step down subsidiary. WBG continues to be a direct subsidiary of the Company.

On 23 November 2016, Wockhardt informed stock exchanges that U.S. Food and Drug Administration ('USFDA') has issued a Warning Letter to C P Pharmaceuticals Limited, Wrexham, United Kingdom, a stepdown Subsidiary of the Company. Currently, there is no business being conducted from C P Pharmaceuticals to the US Market. C P Pharmaceuticals has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.

On 13 December 2016, Wockhardt informed the stock exchanges that UK MHRA has since confirmed that the Company's manufacturing unit at Kadaiya, Daman complies with the principles and guidelines of Good Manufacturing Practices. In view of this, the approval status of the said unit continues.

On 19 December 2016, Wockhardt informed the stock exchanges that UK MHRA has since confirmed that general compliance with the principles and guidelines of Good Manufacturing Practice of the Company's manufacturing unit at L-1, Chikalthana, Aurangabad. In view of this, the approval status of the said unit continues. Further, UK MHRA has considered the said manufacturing unit suitable for Risk based Inspection with reduced inspection frequency of 2 years from the existing inspection frequency of 1 year.

On 5 January 2017, Wockhardt informed the stock exchanges that competent authority, Berlin, Germany has since issued EU GMP Certificate confirming that Company's manufacturing facility at 138, GIDC Estate, Ankaleshwar, Gujarat, complies with the principles and guidelines of Good Manufacturing Practices. The Certificate issued in this regard is valid for 3 years.

On 1 March 2017, Wockhardt informed the stock exchanges that the U.S. Food and Drug Administration ('USFDA') has issued a Warning Letter to Morton Grove Pharmaceuticals Inc., USA, a stepdown Subsidiary of the Company. This would mean that current portfolio of the Company will continue to be made available in the market. However, new approvals will be withheld till resolution. The Company, with the help of the Consultants, has already initiated appropriate measures since last several months to address the issues raised by USFDA.

On 3 April 2017, Wockhardt announced that in a recent meeting between Wockhardt Research team and US FDA New Drug Antibiotic Regulatory team, US FDA agreed to abridged clinical trial for Phase III for Wockhardt's superdrug antibiotic WCK 5222.This was based on the evaluation by US FDA of its preclinical and clinical data of Phase I establishing safety and clinical scope of efficacy for the drug. WCK 5222 is a combination of Zidebactam and Cefepime.

On 29 May 2017, Wockhardt Limited (WL) announced that the Health Products Regulatory Authority of Ireland ('HPRA') has granted Certificate of GMP Compliance to the company's Shendra, Aurangabad facility based on inspection performed from 27 February 2017 to 3 March 2017.

On 22 June 2017, Wockhardt Limited (WL) announced that, WL and two subsidiaries, Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP), in the United Kingdom have settled an ongoing commercial litigation before the High Court in London, United Kingdom in related to a supply contract for a drug named Trisenox. The dispute between the parties was in respect of the price charged by CP to its counterparty to the contract, Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva). Under the above referred settlement between the parties, CP has agreed to waive its claim for the outstanding trade receivable of GBP 20 mn and accordingly dropped its counterclaim for the said amount and further paid a sum of GBP23 mn to Teva and Cephalon by way of full and final settlement of Teva's claims. The High Court has accepted the settlement between the parties and a Consent order was issued on 21 June 2017.

On 7 August 2017, Wockhardt Limited announced that it has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 1gm, and 2gm injections of Oxacillin.Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc. Wockhardt is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy.

The Board of Directors of Wockhardt Limited at its meeting held on 4 May 2018 approved raising of additional capital by way of one or more public or private offerings including through a Qualified Institutions Placement (QIP) to eligible investors through an issuance of equity shares or other eligible securities for an amount not exceeding Rs 1500 crore as may be permitted under applicable law and subject to applicable regulatory and statutory approvals.

With an aim to grow and further establish its international presence in pharmaceutical manufacturing, Wockhardt set up its first facility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG in July 2018.

In FY 2019, US Food and Drugs Administrator (US FDA) carried out inspection of Bioequivalence Centre located at R&D Centre, Aurangabad during which Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited.

As on 31March, 2019, the Company has total 32 Subsidiaries under its roof. During the year, the Company has incorporated 'Wockhardt Medicines Limited' as a Wholly Owned Subsidiary of the Company.

As on 31 March, 2020, Wockhardt has, cumulatively, filed 3,165 patents, and has been granted 722 patents cumulatively.

The Board of Directors of your Company in their meeting held on 12 February, 2020 approved the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the above pharmaceutical products which are being transferred are manufactured (Business Undertaking') by way of a slump sale to Dr. Reddy's Laboratories Limited as per the terms and conditions specified in the Business Transfer Agreement (BTA') for a consideration of Rs 1,850 crore.

Wockhardt, on 03 August 2020 entered into an agreement with the UK Government to fill finish COVID-19 vaccines for which manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID-19, including AZD1222, the vaccine co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.

8 patents were filed during the quarter ended 30 September, 2020 and the cumulative filings are stood at 3173. The company was granted 14 patents during the quarter and now holds 742 patents as on 30 September 2020.

9 patents were filed during the quarter ended 31 December, 2020 and the cumulative filings are stood at 3182. The company was granted 10 patents during the quarter and now holds 752 patents as on 31 December 2020.

On 10th February 2021, Wockhardt announced six-month extension of its agreement with the UK Government to fill-finish COVID-19 vaccines. This expands the original agreement from 18 to 24 months i.e., until August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.

5 patents were filed during the quarter ended 31 March 2021 and the cumulative filings are stood at 3187. The company was granted 11 patents during the quarter and now holds 763 patents as on 31 March, 2021.

During the year 2021, Company launched 2 new antibiotics, EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia.

During the year 2021, Company transferred the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the Business Undertaking), to Dr. Reddy's Laboratories Limited (DRL) for a consideration of Rs. 1,850 crore, subject to adjustments specified in the Business Transfer Agreement (BTA) dated 12th February 2020.

During the year 2021, Wockhardt France (Holdings) S.A.S. (WFH), a Step down Subsidiary of the Company divested the Marketing
Authorisations (MAH) of the products along with their Trademarks (collectively known as Business Assets') for a consideration of Euro 11 Million.

During the year 2022, the Company has filed 41 patent applications and 40 patents were granted during the year of which 36 patents were for NCEs. Accordingly, as on 31st March, 2022, the Company has cumulatively filed 3,228 patents and grants 803 patents .

During the year 2022, Wockhardt Bio AG - a subsidiary of Wockhardt Limited and Jiangxi Jemincare Group Company Limited, China have partnered for Wockhardt's novel patented antibiotic WCK 4873 in People's Republic of China, Hong Kong, Macau and Taiwan for the treatment of community-acquired bacterial pneumonia and other respiratory tract infections. It launched EMROK and EMROK O in India and treated over 20,000 patients.

Phase 3 study involving patients with complicated urinary tract infections started in October 2022. The Company launched its next generation reusable insulin delivery device mypen 2', an ISO 10993 and 11608-certified product with a European design in 2024. It introduced the Mako SmartRoboticsT System for knee and hip replacement surgeries. It also completed the pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873 in 2024.

Parent organization Wockhardt
NSE symbol WOCKPHARMA
Founded 1999
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Wockhardt Ltd?

Answer Field

The share price of Wockhardt Ltd for NSE is ₹ 1296.7 and for BSE is ₹ 1296.7.

What is the Market Cap of Wockhardt Ltd?

Answer Field

The market cap of Wockhardt Ltd for NSE is ₹ 1,86,80.28 Cr. and for BSE is ₹ 1,86,80.28 Cr. as of now.

What is the 52 Week High and Low of Wockhardt Ltd?

Answer Field

The 52 Week High and Low of Wockhardt Ltd for NSE is ₹ 1679.90 and ₹ 490.15 and for BSE is ₹ 1678.60 and ₹ 489.20.

How to Buy Wockhardt Ltd share?

Answer Field

You can trade in Wockhardt Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Wockhardt Ltd?

Answer Field

The 1 year returns on the stock has been 128.91%.

What is the Current Share Price of Wockhardt Ltd?

Answer Field

Wockhardt Ltd share price is for NSE ₹ 1296.7 & for BSE ₹ 1296.7 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Wockhardt Ltd Share?

Answer Field

The market cap of Wockhardt Ltd for NSE ₹ 1,86,80.28 & for BSE ₹ 1,86,80.28 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Wockhardt Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Wockhardt Ltd share is -118.42.

What is the PB ratio of Wockhardt Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Wockhardt Ltd share is 170.15.

How to Buy Wockhardt Ltd Share?

Answer Field

You can trade in Wockhardt Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Wockhardt Ltd Share on Bajaj Broking App?

Answer Field

To buy Wockhardt Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Wockhardt Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|